SIMCERE PHARMAC Financials
| S2P Stock | EUR 0.81 0.01 1.22% |
SIMCERE |
| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | HK0000658531 |
| Sector | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Currency | EUR - Euro |
You should never invest in SIMCERE PHARMAC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of SIMCERE Stock, because this is throwing your money away. Analyzing the key information contained in SIMCERE PHARMAC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
SIMCERE PHARMAC Key Financial Ratios
There are many critical financial ratios that SIMCERE PHARMAC's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that SIMCERE PHARMAC GRP reports annually and quarterly.| Return On Equity | 0.17 | |||
| Return On Asset | 0.0344 | |||
| Beta | 0.48 | |||
| Last Dividend Paid | 0.15 |
SIMCERE Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SIMCERE PHARMAC's current stock value. Our valuation model uses many indicators to compare SIMCERE PHARMAC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SIMCERE PHARMAC competition to find correlations between indicators driving SIMCERE PHARMAC's intrinsic value. More Info.SIMCERE PHARMAC GRP is rated third in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.20 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for SIMCERE PHARMAC GRP is roughly 4.94 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SIMCERE PHARMAC's earnings, one of the primary drivers of an investment's value.SIMCERE PHARMAC GRP Systematic Risk
SIMCERE PHARMAC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SIMCERE PHARMAC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on SIMCERE PHARMAC GRP correlated with the market. If Beta is less than 0 SIMCERE PHARMAC generally moves in the opposite direction as compared to the market. If SIMCERE PHARMAC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SIMCERE PHARMAC GRP is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SIMCERE PHARMAC is generally in the same direction as the market. If Beta > 1 SIMCERE PHARMAC moves generally in the same direction as, but more than the movement of the benchmark.
SIMCERE PHARMAC December 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SIMCERE PHARMAC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SIMCERE PHARMAC GRP. We use our internally-developed statistical techniques to arrive at the intrinsic value of SIMCERE PHARMAC GRP based on widely used predictive technical indicators. In general, we focus on analyzing SIMCERE Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SIMCERE PHARMAC's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.34 | |||
| Information Ratio | 0.0729 | |||
| Maximum Drawdown | 18.98 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 5.13 |
Complementary Tools for SIMCERE Stock analysis
When running SIMCERE PHARMAC's price analysis, check to measure SIMCERE PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SIMCERE PHARMAC is operating at the current time. Most of SIMCERE PHARMAC's value examination focuses on studying past and present price action to predict the probability of SIMCERE PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SIMCERE PHARMAC's price. Additionally, you may evaluate how the addition of SIMCERE PHARMAC to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |